Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats

被引:55
作者
Abe, M [1 ]
Shibata, K
Akatsu, H
Shimizu, N
Sakata, N
Katsuragi, T
Okada, H
机构
[1] Fukuoka Univ, Sch Med, Dept Pharmacol, Fukuoka 8140180, Japan
[2] Fukuoka Univ, Sch Med, Biodynam Lab, Fukuoka 8140180, Japan
[3] Fukuoka Univ, Sch Med, Dept Pathol 2, Fukuoka 8140180, Japan
[4] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi, Japan
[5] Nagoya City Univ, Sch Med, Dept Mol Biol, Nagoya, Aichi 467, Japan
关键词
D O I
10.4049/jimmunol.167.8.4651
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R-L tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.
引用
收藏
页码:4651 / 4660
页数:10
相关论文
共 37 条
[1]
cDNA cloning and characterization of rat C5a anaphylatoxin receptor [J].
Akatsu, H ;
Miwa, T ;
Sakurada, C ;
Fukuoka, Y ;
Ember, JA ;
Yamamoto, T ;
Hugli, TE ;
Okada, H .
MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (07) :575-580
[2]
Barnes PJ, 1998, PHARMACOL REV, V50, P515
[3]
Cutting edge:: Guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease:: Evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma [J].
Bautsch, W ;
Hoymann, HG ;
Zhang, QW ;
Meier-Wiedenbach, I ;
Raschke, U ;
Ames, RS ;
Sohns, B ;
Flemme, N ;
zu Vilsendorf, AM ;
Grove, M ;
Klos, A ;
Köhl, J .
JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5401-5405
[4]
Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulation and respiratory burst [J].
Binder, R ;
Kress, A ;
Kan, GZ ;
Herrmann, K ;
Kirschfink, M .
MOLECULAR IMMUNOLOGY, 1999, 36 (13-14) :885-892
[5]
Asthma - From bronchoconstriction to airways inflammation and remodeling [J].
Bousquet, J ;
Jeffery, PK ;
Busse, WW ;
Johnson, M ;
Vignola, AM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (05) :1720-1745
[6]
EOSINOPHILIC INFLAMMATION IN ASTHMA [J].
BOUSQUET, J ;
CHANEZ, P ;
LACOSTE, JY ;
BARNEON, G ;
GHAVANIAN, N ;
ENANDER, I ;
VENGE, P ;
AHLSTEDT, S ;
SIMONYLAFONTAINE, J ;
GODARD, P ;
MICHEL, FB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1033-1039
[7]
Late-phase inflammation: Influence on morbidity [J].
Charlesworth, EN .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (06) :S291-S297
[8]
de Bie JJ, 2000, EXP LUNG RES, V26, P491
[9]
de Bruin-Weller MS, 1999, CLIN EXP ALLERGY, V29, P159
[10]
DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373